Analysen von Cory Kasimov
| 10.05.22 | BioNTech (ADRs) Neutral | JP Morgan Chase & Co. | |
| 31.03.22 | BioNTech (ADRs) Neutral | JP Morgan Chase & Co. | |
| 10.11.21 | BioNTech (ADRs) Neutral | JP Morgan Chase & Co. | |
| 28.04.21 | Amgen Neutral | JP Morgan Chase & Co. | |
| 31.03.21 | BioNTech (ADRs) Neutral | JP Morgan Chase & Co. | |
| 05.03.21 | Amgen Neutral | JP Morgan Chase & Co. | |
| 11.11.20 | BioNTech (ADRs) Neutral | JP Morgan Chase & Co. | |
| 29.07.20 | Amgen Neutral | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 25.01.20 | Amgen Neutral | JP Morgan Chase & Co. | |
| 30.01.19 | Amgen Neutral | JP Morgan Chase & Co. | |
| 07.08.12 | ImmunoGen neutral | JP Morgan Chase & Co. | |
| 18.07.12 | Human Genome Sciences neutral | JP Morgan Chase & Co. | |
| 22.06.12 | Onyx Pharmaceuticals overweight | JP Morgan Chase & Co. | |
| 24.02.12 | Vivus overweight | JP Morgan Chase & Co. | |
| 05.08.11 | Dendreon overweight | JP Morgan Chase & Co. | |